Today's Daily Dose brings you news about Intellipharmaceutics' upcoming regulatory catalyst; SteadyMed's progress with lead drug product candidate, Trevyent; Theratechnologies' new antiretroviral treatment in the making; Aeterna's second try for growth hormone drug Macrilen, and preliminary clinical data from Part 1 of a phase II trial of PTC Therapeutics' RG7916 in spinal muscular atrophy.
from RTT - Biotech http://ift.tt/2uyWWyD
via IFTTT
No comments:
Post a Comment